Transporter-Dependent Cytotoxicity of Antiviral Drugs in Primary Cultures of T Human Proximal Tubular Cells ⁎ Lawrence H

Total Page:16

File Type:pdf, Size:1020Kb

Transporter-Dependent Cytotoxicity of Antiviral Drugs in Primary Cultures of T Human Proximal Tubular Cells ⁎ Lawrence H Toxicology 404–405 (2018) 10–24 Contents lists available at ScienceDirect Toxicology journal homepage: www.elsevier.com/locate/toxicol Transporter-dependent cytotoxicity of antiviral drugs in primary cultures of T human proximal tubular cells ⁎ Lawrence H. Lasha, , Caroline A. Leeb, Clynn Wilkerb,1, Vishal Shahb,2 a Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield Avenue, Detroit, MI 48201 USA b Ardea Biosciences, San Diego, CA 92121 USA ARTICLE INFO ABSTRACT Keywords: The role of plasma membrane transporters in the nephrotoxicity of two antiretroviral drugs, cidofovir and te- Antiviral drugs nofovir, was studied in primary cultures of human proximal tubular (hPT) cells. Cells were grown on Transwell Nephrotoxicity filter inserts to maintain epithelial polarity and access to either the apical or basolateral plasma membrane. The Human proximal tubular cells function of relevant membrane transporters, organic anion transporter 1 and 3 (OAT1/3), P-glycoprotein Biomarkers (multidrug resistance protein-1; P-gp or MDR1), and organic cation transporter 2 (OCT2), was validated by Membrane transport measurements of apical-to-basolateral and basolateral-to-apical fluxes of furosemide, digoxin, and metformin, respectively. Acute cytotoxicity of cidofovir (0, 10, 50, 150, or 300 μM) in the absence or presence of 500 μM probenecid, tenofovir disoproxil fumarate (0, 20, 90, 180, or 360 μM) in the absence or presence of 500 μM probenecid, or cisplatin (0, 20, 90, 180, or 360 μM) as a positive control in the absence or presence of 500 μM cimetidine, was assessed after 4-h incubations by determinations of release of lactate dehydrogenase (LDH), γ- glutamyltransferase (GGT), N-acetyl-β-D-glucosaminidase (NAG), or Kidney Injury Molecule-1 (KIM-1). Cell death generally agreed with each of the four biomarkers, was generally greater when cidofovir or tenofovir was added to the upper compartment, and was markedly diminished in the presence of the appropriate transport inhibitor. Additionally, the extent of cytotoxicity caused by the two antiviral drugs was similar to that caused by cisplatin. The results demonstrate the importance of plasma membrane transport of antiviral drugs to elicit cytotoxicity in the hPT cell. 1. Introduction laboratory animals (Lacy et al., 1998) and humans (Lalezari et al., 1995) showed protection with probenecid. In fact, co-administration Antiretroviral (ARV) drugs have become key therapeutics against with probenecid and intravenous saline hydration became the normal such infectious agents as human immunodeficiency virus (HIV), hepa- treatment protocol (Lea and Bryson, 1996). An advantage over pre- titis B, cytomegalovirus, and other herpes viruses. As with many che- viously developed ARVs was that cidofovir does not require viral acti- motherapeutics, however, their clinical use is often limited by non- vation (Lalezari, 1997), but is activated by phosphorylation by cellular target organ toxicities. Two of the most important ARVs are cidofovir enzymes to inhibit viral DNA polymerase (Lea and Bryson, 1996). Ci- and tenofovir. dofovir also has efficacy against a broad range of viruses, including Cidofovir was approved by the U.S. Food and Drug Administration refractory and premalignant human papillomavirus (Coremans and in 1996 as an antiviral nucleoside analogue with potent activity against Snoeck, 2009). Despite reports of nephrotoxicity, a carefully designed cytomegalovirus and other herpes viruses. However, it was found to therapeutic regimen can allow cidofovir to be used without ne- exhibit dose-limiting nephrotoxicity (News, 1997). Studies in both phrotoxicity being a limiting problem (Araya et al., 2008). Abbreviations: ARV, antiretroviral; CHO, Chinese Hamster Ovary; CID, collision-induced dissociation; DMEM/F12, Dulbecco’s Modified Eagle’s Medium: Ham’s F12 Medium; DMF, dimethylformamide; DMSO, dimethylsulfoxide; GGT, γ-glutamyltransferase; HIV, human immunodeficiency; hPT, human proximal tubular; IS, internal standard; JAB, apical-to-baso- lateral flux; JBA, basolateral-to-apical flux; KIM-1, Kidney Injury Molecule-1; LC–MS/MS, liquid chromatography-mass spectrometry/mass-spectrometry; LDH, lactate dehydrogenase; MATE1, multidrug and toxin extrusion protein 1; MRM, multiple reaction monitoring; MRP, multidrug resistance-associated protein; NAG, N-acetyl-β-D-glucosaminidase; OAT, organic anion transporter; OATP, organic anion-transporting polypeptide; OCT, organic cation transporter; PBS, phosphate-buffered saline; P-gp, P-glycoprotein (also called MDR1, multidrug resistance protein 1); PT, proximal tubular; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TISP, turbo ionspray ⁎ Corresponding author. E-mail address: [email protected] (L.H. Lash). 1 Current address: Heron Therapeutics, 12707 High Bluff Drive, Suite 200, San Diego, CA 92130, USA. 2 Current address: Organovo Holdings, Inc., 6275 Nancy Ridge Drive, Suite 110, San Diego, CA 92121, USA. https://doi.org/10.1016/j.tox.2018.05.002 Received 19 December 2017; Received in revised form 10 April 2018; Accepted 2 May 2018 Available online 05 May 2018 0300-483X/ © 2018 Elsevier B.V. All rights reserved. L.H. Lash et al. Toxicology 404–405 (2018) 10–24 Effective transport into renal proximal tubular (PT) cells is an im- 2. Materials and methods portant component for many nephrotoxic agents. Cidofovir is transported into renal PT cells by the human organic anion transporter 1 (hOAT1; 2.1. Experimental design SLC22A6), as demonstrated in Chinese Hamster Ovary (CHO) cells stably transfected with hOAT1 cDNA (Ho et al., 2000). Intracellular accumu- For all studies, cells were grown to approximately 90% confluence ® lation of cidofovir in transfectants was > 100-fold higher than in par- on collagen-coated Transwell inserts (6-well, 0.4-μm pore size) with ental CHO cells, and this accumulation was associated with enhanced serum-free, hormonally-defined Dulbecco’s Modified Eagle’s Medium: cytotoxicity, which was reduced by addition of the OAT1 inhibitor pro- Ham’s F12 Medium (DMEM/F12; 1/1; 3.0 ml in upper compartment, benecid. This is consistent with the clinical data described above, 1.5 ml in lower compartment), as done previously for transport studies showing that co-administration of cidofovir with probenecid diminished in hPT cells (Lash et al., 2006). As hPT cells grow with their brush nephrotoxicity. Diminished capacity for excretion is another important border facing upwards and their basal membrane on the growth sur- factor: Cundy et al. (1996) found a prolonged elimination phase for ci- face, the upper compartment is functionally analogous to the tubular dofovir in African Green Monkeys, consistent with a long intracellular lumen whereas the lower compartment is functionally analogous to the half-life for the phosphorylated form of the drug. interstitial fluid and nearby perfusing capillaries. Accordingly, for Although most of the mechanistic studies on cidofovir have been transport studies, addition of drug to the lower compartment followed performed in transfected cell lines, Ortiz et al. (2005) showed that ci- by measurement of drug in the upper compartment allows one to dofovir caused a time- (peak at 7 days) and concentration- (10–40 μg/ measure basolateral-to-apical flux (JBA) whereas addition of drug to the ml) dependent incidence of apoptosis in primary cultures of human upper compartment followed by measurement of drug in the lower proximal tubular (hPT) cells. Such a pattern was concluded to be con- compartment allows one to measure apical-to-basolateral flux (JAB). sistent with that of clinical toxicity. Apoptosis was prevented by pro- Similarly, for cytotoxicity studies, addition of drug to the lower com- benecid, again demonstrating the critical role of membrane transport in partment along with appropriate transport inhibitors allows one to as- cytotoxicity. sess the importance of basolateral plasma membrane transporters in Tenofovir, originally given as the disoproxil fumarate preparation determining cytotoxicity whereas addition of drug to the upper com- (TDF), was the first nucleotidic inhibitor of HIV reverse transcription partment along with appropriate transport inhibitors allows one to as- and became available in 2001. It has been extensively used worldwide sess the importance of apical plasma membrane transporters in de- and is the most prescribed ARV drug. Early clinical trials suggested that termining cytotoxicity. TDF was safer than other ARVs. Even as early as 2001, however, cases We took a conservative approach by evaluating toxicity at relatively of TDF-induced nephrotoxicity were reported and such occurrences high concentrations and a short incubation time to detect toxicity. As were considered a potentially serious dose-limiting side effect (Foisy transporters are involved in the uptake of these drugs, their con- et al., 2013; Gupta et al., 2012; Hall, 2013; Mitra et al., 2014; centrations would mimic their accumulation and if toxicity could be Monteagudo-Cho et al., 2012; Mouton et al., 2016; Tourret et al., 2013). detected in a short-term incubation, then this decreases the risk of As noted in a recent review (Murphy and Valentovic, 2017), changes in missing a true toxicity effect. Moreover, cytotoxicity of other ne- dosing of tenofovoir are needed in the presence of renal impairment. phrotoxic chemotherapeutic agents has previously been determined at Risk factors for development of tenofovir-induced nephrotoxicity in- 1, 2, 4, and 24 h of incubation (Gallardo-Godoy et al., 2016; Huang
Recommended publications
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------WARNINGS AND PRECAUTIONS--------------------­ These highlights do not include all the information needed to use • New onset or worsening renal impairment: Can include acute VIREAD safely and effectively. See full prescribing information renal failure and Fanconi syndrome. Assess creatinine clearance for VIREAD. (CrCl) before initiating treatment with VIREAD. Monitor CrCl and ® serum phosphorus in patients at risk. Avoid administering VIREAD (tenofovir disoproxil fumarate) tablets, for oral use VIREAD with concurrent or recent use of nephrotoxic drugs. (5.3) VIREAD® (tenofovir disoproxil fumarate) powder, for oral use • Coadministration with Other Products: Do not use with other Initial U.S. Approval: 2001 tenofovir-containing products (e.g., ATRIPLA, COMPLERA, and TRUVADA). Do not administer in combination with HEPSERA. WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH (5.4) STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS • HIV testing: HIV antibody testing should be offered to all HBV- infected patients before initiating therapy with VIREAD. VIREAD See full prescribing information for complete boxed warning. should only be used as part of an appropriate antiretroviral • Lactic acidosis and severe hepatomegaly with steatosis, combination regimen in HIV-infected patients with or without HBV including fatal cases, have been reported with the use of coinfection. (5.5) nucleoside analogs, including VIREAD. (5.1) • Decreases in bone mineral density (BMD): Consider assessment • Severe acute exacerbations of hepatitis have been reported of BMD in patients with a history of pathologic fracture or other in HBV-infected patients who have discontinued anti- risk factors for osteoporosis or bone loss. (5.6) hepatitis B therapy, including VIREAD. Hepatic function • Redistribution/accumulation of body fat: Observed in HIV-infected should be monitored closely in these patients.
    [Show full text]
  • Novel Therapeutics for Epstein–Barr Virus
    molecules Review Novel Therapeutics for Epstein–Barr Virus Graciela Andrei *, Erika Trompet and Robert Snoeck Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] (E.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +32-16-321-915 Academic Editor: Stefano Aquaro Received: 15 February 2019; Accepted: 4 March 2019; Published: 12 March 2019 Abstract: Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.
    [Show full text]
  • Treatment of Warts with Topical Cidofovir in a Pediatric Patient
    Volume 25 Number 5| May 2019| Dermatology Online Journal || Case Report 25(5):6 Treatment of warts with topical cidofovir in a pediatric patient Melissa A Nickles BA, Artem Sergeyenko MD, Michelle Bain MD Affiliations: Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, llinois, USA Corresponding Author: Artem Sergeyenko MD, 808 South Wood Street Suite 380, Chicago, IL 60612, Tel: 847-338-0037, Email: a.serge04@gmail topical cidofovir is effective in treating HPV lesions Abstract and molluscum contagiosum in adult patients with Cidofovir is an antiviral nucleotide analogue with HIV/AIDS [2]. Case reports have also found topical relatively new treatment capacities for cidofovir to effectively treat anogenital squamous dermatological conditions, specifically verruca cell carcinoma (SCC), bowenoid papulosis, vulgaris caused by human papilloma virus infection. condyloma acuminatum, Kaposi sarcoma, and HSV-II In a 10-year old boy with severe verruca vulgaris in adult patients with HIV/AIDS [3]. Cidofovir has recalcitrant to multiple therapies, topical 1% experimentally been shown to be effective in cidofovir applied daily for eight weeks proved to be an effective treatment with no adverse side effects. treating genital condyloma acuminata in adult This case report, in conjunction with multiple immunocompetent patients [4] and in a pediatric published reports, suggests that topical 1% cidofovir case [5]. is a safe and effective treatment for viral warts in Cidofovir has also been used in pediatric patients to pediatric patients. cure verruca vulgaris recalcitrant to traditional treatment therapies. There have been several reports Keywords: cidofovir, verruca vulgaris, human papilloma that topical 1-3% cidofovir cream applied once or virus twice daily is effective in treating verruca vulgaris with no systemic side effects and low rates of recurrence in immunocompetent children [6-8], as Introduction well as in immunocompromised children [9, 10].
    [Show full text]
  • Annex I Summary of Product Characteristics
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 4 1. NAME OF THE MEDICINAL PRODUCT VISTIDE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cidofovir equivalent to 375 mg/5 ml (75 mg/ml) cidofovir anhydrous. The formulation is adjusted to pH 7.4. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion 4. CLINICAL PARTICULARS 4.1 Therapeutic Indication Cidofovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Until further experience is gained, cidofovir should be used only when other agents are considered unsuitable. 4.2 Posology and Method of Administration Before each administration of cidofovir, serum creatinine and urine protein levels should be investigated. The recommended dosage, frequency, or infusion rate must not be exceeded. Cidofovir must be diluted in 100 milliliters 0.9% (normal) saline prior to administration. To minimise potential nephrotoxicity, oral probenecid and intravenous saline prehydration must be administered with each cidofovir infusion. Dosage in Adults • Induction Treatment. The recommended dose of cidofovir is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over 1 hr) administered once weekly for two consecutive weeks. • Maintenance Treatment. Beginning two weeks after the completion of induction treatment, the recommended maintenance dose of cidofovir is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over 1 hr) administered once every two weeks. Cidofovir therapy should be discontinued and intravenous hydration is advised if serum creatinine increases by = 44 µmol/L (= 0.5 mg/dl), or if persistent proteinuria = 2+ develops. • Probenecid.
    [Show full text]
  • Silibinin Component for the Treatment of Hepatitis Silbininkomponente Zur Behandlung Von Hepatitis Composant De Silibinine Pour Le Traitement De L’Hépatite
    (19) & (11) EP 2 219 642 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/357 (2006.01) A61P 1/16 (2006.01) 21.09.2011 Bulletin 2011/38 A61P 31/12 (2006.01) (21) Application number: 08849759.9 (86) International application number: PCT/EP2008/009659 (22) Date of filing: 14.11.2008 (87) International publication number: WO 2009/062737 (22.05.2009 Gazette 2009/21) (54) SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS SILBININKOMPONENTE ZUR BEHANDLUNG VON HEPATITIS COMPOSANT DE SILIBININE POUR LE TRAITEMENT DE L’HÉPATITE (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A-02/067853 GB-A- 2 167 414 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR • POLYAK STEPHEN J ET AL: "Inhibition of T- cell inflammatory cytokines, hepatocyte NF-kappa B (30) Priority: 15.11.2007 EP 07022187 signaling, and HCV infection by standardized 15.11.2007 US 988168 P silymarin" GASTROENTEROLOGY, vol. 132, no. 25.03.2008 EP 08005459 5, May 2007 (2007-05), pages 1925-1936, XP002477920 ISSN: 0016-5085 (43) Date of publication of application: • MAYER K E ET AL: "Silymarin treatment of viral 25.08.2010 Bulletin 2010/34 hepatitis: A systematic review" JOURNAL OF VIRAL HEPATITIS 200511 GB, vol. 12, no. 6, (60) Divisional application: November 2005 (2005-11), pages 559-567, 11005445.9 XP002477921 ISSN: 1352-0504 1365-2893 • CHAVEZ M L: "TREATMENT OF HEPATITIS C (73) Proprietor: Madaus GmbH WITH MILK THISTLE?" JOURNAL OF HERBAL 51067 Köln (DE) PHARMACOTHERAPY, HAWORTH HERBAL PRESS, BINGHAMTON, US, vol.
    [Show full text]
  • Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
    pharmaceuticals Review Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection Isabella Zanella 1,2,* , Daniela Zizioli 1, Francesco Castelli 3 and Eugenia Quiros-Roldan 3 1 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; [email protected] 2 Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy 3 University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; [email protected] (F.C.); [email protected] (E.Q.-R.) * Correspondence: [email protected]; Tel.: +39-030-399-6806 Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations. Age and comorbidities may explain severity in critical cases and people living with human immunodeficiency virus (HIV) might be at particularly high risk for severe progression. Nonetheless, current data, although sometimes contradictory, do not confirm higher morbidity, risk of more severe COVID-19 or higher mortality in HIV-infected people with complete access to antiretroviral therapy (ART). A possible protective role of ART has been hypothesized to explain these observations. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment; this is also based on previous studies on severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV). Among Citation: Zanella, I.; Zizioli, D.; them, lopinavir/ritonavir, an inhibitor of viral protease, was extensively used early in the pandemic Castelli, F.; Quiros-Roldan, E.
    [Show full text]
  • Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patien
    1 2 3 PROJECT TITLE 4 Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent 5 Patients in Critical Care 6 7 STUDY ACRONYM 8 Cytomegalovirus Control in Critical Care - CCCC 9 10 APPLICANTS 11 Dr Nicholas Cowley 12 Specialty Registrar Anaesthesia and Intensive Care Medicine, Intensive Care Research Fellow 13 Queen Elizabeth Hospital Birmingham 14 15 Professor Paul Moss 16 Professor of Haematology 17 Queen Elizabeth Hospital Birmingham 18 19 Professor Julian Bion 20 Professor of Intensive Care Medicine 21 Queen Elizabeth Hospital Birmingham 22 23 Trial Virologist Trial Statistician 24 Dr H Osman Dr P G Nightingale 25 Queen Elizabeth Hospital Birmingham University of Birmingham CCCC CMV Protocol V1.7, 18th September 2013 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 26 CONTENTS 27 Substantial Amendment Sept 18th 2013 4 28 1 SUMMARY OF TRIAL DESIGN .......................................................................................................... 5 29 2 QEHB ICU Duration of Patient Stay ................................................................................................. 6 30 3 SCHEMA - QEHB PATIENT NUMBERS AVAILABLE FOR RECRUITMENT ........................................... 6 31 4 INTRODUCTION ............................................................................................................................... 7 32 4.1 CMV latent infection is widespread ........................................................................................ 7 33 4.2 CMV Reactivation
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Valganciclovir Accord 450mg film coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film -coated tablet contains 496.3 mg valganciclovir hydrochloride equivalent to 450 mg of valganciclovir (as free base). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film -coated tablet. 16.7 x 7.8 mm approx., pink, oval, biconvex film coated tablets debossed with ‘J’ on one side and ‘156 ’ on the other side. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Valganciclovir Accord is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir Accord is indicated for the prevention of CMV disease in CMV -negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV -positive donor. 4.2 Posology and method of administration Posology Caution – Strict adherence to dosage recommendations is essential to avoid overdose; see sections 4.4 and 4.9. Valganciclovir is rapidly and extensively metabolised to ganciclovir after oral dosing. Oral valganciclovir 900 mg b.i.d. is therapeutically equivalent to intravenous ganciclovir 5 mg/kg b.i.d. Treatment of cytomegalovirus (CMV) retinitis Adult patients Induction treatment of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg valganciclovir (two Valganciclovir Accord 450 mg tablets) twice a day for 21 days and, whenever possible, taken with food. Prolonged induction treatment may increase the risk of bone marrow toxicity (see section 4.4).
    [Show full text]
  • Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2
    viruses Review Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 Lauren A. Sadowski 1,†, Rista Upadhyay 1,2,†, Zachary W. Greeley 1,‡ and Barry J. Margulies 1,3,* 1 Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA; [email protected] (L.A.S.); [email protected] (R.U.); [email protected] (Z.W.G.) 2 Towson University Department of Chemistry, Towson, MD 21252, USA 3 Molecular Biology, Biochemistry, and Bioinformatics Program, Towson University, Towson, MD 21252, USA * Correspondence: [email protected] † Authors contributed equally to this manuscript. ‡ Current address: Becton-Dickinson, Sparks, MD 21152, USA. Abstract: Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaher- pesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses. Keywords: acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfi- navir; HSV-1; HSV-2 Citation: Sadowski, L.A.; Upadhyay, R.; Greeley, Z.W.; Margulies, B.J. Current Drugs to Treat Infections 1. Introduction with Herpes Simplex Viruses-1 and -2. The world of anti-herpes simplex (anti-HSV) agents took flight in 1962 with the FDA Viruses 2021, 13, 1228.
    [Show full text]
  • Specialty Drug List 10-24-11
    Iowa Medicaid Specialty Drug List Effective 10/24/2011 “Specialty” drugs include biological drugs, blood-derived products, complex molecules, and select oral, injectable, and infused medications identified by the Department and reimbursed at AWP-17% plus the dispensing fee. Specialty pricing will be applied to both the brand and generic drug products. NOTE: See the PDL at www.iowamedicaidpdl.com for specific PA criteria for the following drugs. BRAND NAME GENERIC NAME AGENTS FOR GAUCHER DISEASE VPRIV velaglucerase alfa ALS RILUTEK riluzole ALCOHOL DEPENDENCE VIVITROL naltrexone AMINOGLYCOSIDES TOBI tobramycin ANTI-ASTHMATICS ALPHA PROTEINASE INHIBITORS ARALAST proteinase inhibitor ARALAST NP proteinase inhibitor PROLASTIN, C proteinase inhibitor ANTIASTHMATIC - BETA - ADRENERGICS BRETHINE INJECTION turbutaline sulfate ANTIBIOTICS - MISC. CAYSTON aztreonam lysine for inhal soln ANTI-CATAPLECTIC AGENTS XYREM sodium oxybate oral solution ANTICOAGULANTS ARIXTRA fondaparinux sodium FRAGMIN dalteparin sodium INNOHEP tinzaparin sodium LOVENOX enoxaparin sodium ANTICONVULSANTS SABRIL vigabatrin ANTIDOTES - CHELATING AGENTS CHEMET succimer EXJADE deferasirox tab for oral susp ANTIEMETIC - TETRAHYDROCANNABINOL (THC) DERIVATIVES MARINOL dronabinol ANTIFUNGALS AMBISOM amphotericin B Liposome IV for suspension ANCOBON flucytosine CANCIDAS caspofungin acetate for IV solution Page 1 of 11 ANTIFUNGALS - ASSORTED NOXAFIL posaconazole VFEND voriconazole ANTIHEMOPHILIC AGENTS ADVATE factor 8 ALPHANATE factor 8 ALPHANINE SD factor 9 AUTOPLEX T anti-inhibitor
    [Show full text]
  • Valganciclovir As Add-On to Standard Therapy in Glioblastoma Patients
    Published OnlineFirst May 18, 2020; DOI: 10.1158/1078-0432.CCR-20-0369 CLINICAL CANCER RESEARCH | CLINICAL TRIALS: TARGETED THERAPY Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients Giuseppe Stragliotto1,2, Mattia Russel Pantalone1,2, Afsar Rahbar1,2, Jiri Bartek3,4, and Cecilia Soderberg-Naucler€ 1,2 ABSTRACT ◥ Purpose: Several groups have reported a prevalence of human Results: Patients with newly diagnosed glioblastoma receiving cytomegalovirus (CMV) in glioblastoma close to 100%. Previously, valganciclovir had longer median overall survival (OS 24.1 vs. we reported that treatment with the antiviral drug valganciclovir 13.3 months, P < 0.0001) and a 2-year survival rate (49.8% vs. as an add-on to standard therapy significantly prolonged survival 17.3%) than controls. Median time-to-tumor progression was in 50 patients with glioblastoma. Here, we present an updated also longer than in controls; 9.9 (0.7–67.5 months) versus retrospective analysis that includes an additional 52 patients. 7.3 (1.2–49 months), P ¼ 0.0003. Valganciclovir improved Patients and Methods: From December 2006 to November survival in patients with radical or partial resection and an 2019, 102 patients with newly diagnosed glioblastoma received unmethylated or methylated MGMT promoter gene. valganciclovir as an add-on to standard therapy. No additional Conclusions: Valganciclovir prolonged median OS of patients toxicity was observed. Contemporary controls were 231 patients with newly diagnosed glioblastoma (with methylated or unmethy- with glioblastoma who received similar baseline therapy. lated MGMT promoter gene) and was safe to use. Introduction to transform cells in vitro (19) and established tumors in immuno- deficient mice (19, 20).
    [Show full text]